1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Gastrointestinal Agents Market
2.3. Global Gastrointestinal Agents Market, By Drug Class, 2025 (US$ Million)
2.4. Global Gastrointestinal Agents Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Gastrointestinal Agents Market: Competitive Analysis
3.1. Market Positioning of Key Gastrointestinal Agents Market Vendors
3.2. Strategies Adopted by Gastrointestinal Agents Market Vendors

4. Gastrointestinal Agents Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Gastrointestinal Agents Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Antidiarrheal
5.3.2. Anti-emetics
5.3.2.1. Anticholinergic Agents
5.3.2.2. Antihistamines
5.3.2.3. Serotonin 5-HT3 Receptor Antagonists
5.3.2.4. Cannabinoid Receptor Agonists
5.3.3. Anti-ulcers
5.3.3.1. Histamine type 2 receptor blockers (H2 blockers)
5.3.3.2. Proton Pump Inhibitors
5.3.4. Laxatives
5.3.5. Inflammatory bowel disease
5.3.5.1. 5-Aminosalicyclic Acid (5-ASA) Derivatives
5.3.5.2. Immunosuppressive Agents
5.3.5.3. Tumor Necrosis Factor Antagonists
5.3.6. Irritable bowel syndrome
5.3.6.1. Antimuscarinics/Antispasmodics
5.3.6.2. Prokinetic Agents

6. North America Gastrointestinal Agents Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
6.3. Gastrointestinal Agents Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)

7. UK and European Union Gastrointestinal Agents Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3. Gastrointestinal Agents Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)

8. Asia Pacific Gastrointestinal Agents Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3. Gastrointestinal Agents Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)

9. Latin America Gastrointestinal Agents Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
9.3. Gastrointestinal Agents Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)

10. Middle East and Africa Gastrointestinal Agents Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
10.3. Gastrointestinal Agents Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2024-2034, USD (Million)

11. Company Profile
11.1. Abbott Laboratories (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Allergan Plc. (Formerly Actavis Plc.)
11.3. AstraZeneca
11.4. Bayer AG
11.5. Boehringer Ingelheim GmbH
11.6. GlaxoSmithKline plc.
11.7. Janssen Biotech, Inc.
11.8. Ranbaxy Laboratories Limited
11.9. Sanofi
11.10. Takeda Pharmaceutical
11.11. Valeant Pharmaceuticals, Inc.